Cardiac allograft rejection

Area of Science:

• Cardiology
• Immunology
• Transplantation Medicine

Background:

• Improved immunosuppressive therapies have reduced cardiac allograft rejection and infection rates.
• Cardiac allograft rejection remains a primary cause of morbidity and mortality, especially within the first year post-transplant.
• The endomyocardial biopsy is a crucial diagnostic tool for identifying rejection.

Purpose of the Study:

• To review the current diagnostic strategies for cardiac allograft rejection.
• To discuss advances in non-invasive evaluation methods for rejection.
• To cover antibody detection and treatment protocols for cardiac allograft rejection.

Main Methods:

• Review of current literature on cardiac allograft rejection diagnosis and treatment.
• Discussion of traditional endomyocardial biopsy findings.
• Exploration of emerging non-invasive diagnostic techniques and antibody detection assays.

Main Results:

• Acute cellular rejection is well-recognized, while antibody-mediated rejection is increasingly diagnosed and linked to worse outcomes.
• Antibody-mediated rejection is associated with increased graft dysfunction, cardiac allograft vasculopathy, and mortality.
• Advances in non-invasive methods and antibody detection offer new avenues for monitoring rejection.

Conclusions:

• Cardiac allograft rejection diagnosis relies on a combination of traditional and novel methods.
• Understanding and timely diagnosis of both cellular and antibody-mediated rejection are critical for patient outcomes.
• Future directions include refining non-invasive diagnostics and optimizing rejection treatment strategies.